US · Healthcare · Diagnostics & Research
EPS came in at -0.05 against a street estimate of -0.07 — a beat of 28.6%.
Analysts rate Opko Health Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.15.
| Fund | Stake |
|---|---|
| Rubric Capital Management LP | 6.40% |
| BlackRock Inc | 4.95% |
| Vanguard Capital Management, LLC | 2.01% |
| Vanguard Portfolio Management, LLC | 2.00% |
| Geode Capital Management, LLC | 1.55% |
| State Street Corp | 1.38% |
| The Goldman Sachs Group Inc | 0.94% |
| UBS Group AG | 0.67% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $65,414,000, up from $56,425,000 in the third quarter of 2025. • Nine-month 2026 revenue was $206 | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 continuing-operations revenue rose to $65.4 million from $56.4 million in the prior-year quarter. • Continuing | 2026-11-04 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • OPKO Health has agreed to sell certain BioReference Health laboratory testing assets to Laboratory Corporation of America Holdings | 2026-10-15 |
| Company announcement · Q3 2026 CONVERTIBLE NOTES • OPKO Health’s approximately $121 million of outstanding 3.75% Convertible Senior Notes due 2029 became convertible by holders thr | 2026-10-02 |
| Material agreement · Q3 2026 OPKO HEALTH, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company issued $125,000,000 in additional senior secured notes on August 13, 2026 • Notes mature | 2026-08-14 |
| Quarterly report · Q2 2026 OPKO HEALTH, INC. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Total Revenues (6 months ended June 30, 2026): $287.8 million vs. $306.8 million (2025 | 2026-07-27 |
| Results announced · Q3 2026 OPKO HEALTH Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $163.5 million vs. $156.8 million in Q2 2025 (+4.3%) • Q2 2026 Net Lo | 2026-07-27 |
| Shareholder vote results · Q2 2026 OPKO HEALTH, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 18, 2026 • 11 Board directors elected with strong approval margins • Tot | 2026-06-18 |
Readable in the app.
| Announcement | Date |
|---|---|
| Agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp OPKO Health agreed to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722 million in cash at closing, subject to adjustments, plus up to $150 million over | 2026-11-04 |
| OPKO Health agrees to sell BioReference assets to Laboratory Corporation of America OPKO Health, through its subsidiary BioReference Health, signed an asset purchase agreement dated October 14, 2026 to sell specified BioReference assets and operations to Laboratory Corporat | 2026-10-15 |
| Research collaboration with Regeneron for multispecific antibody development OPKO Health reported Q4 2025 results with mixed financial performance but significant pipeline progress. Revenues declined to $148.5M from $183.6M year-over-year due to asset sales, and the | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Opko Health Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.